Prognostic Utility of the Pan-Immune-Inflammation Value (PIV) in Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy
Cancers · 11.11.2026 · 18 (22) · 3605
DOI: 10.3390/cancers18223605 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 11.11.2026. Verfasst von Liming Gu und 4 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Wuxi Municipal Health Commission, Wuxi Bureau of Science and Technology.
Abstract (Originalsprache)
Background
Cervical cancer remains a leading cause of cancer-related mortality in women. CCRT is standard for LACC, but its efficacy varies. This study was designed to evaluate the prognostic value of PIV in predicting short-term efficacy and long-term survival in LACC patients receiving CCRT.
Methods
We retrospectively analyzed 205 patients with stage IB3–IVA cervical cancer treated with CCRT at the Affiliated Hospital of Jiangnan University (2018–2024). Variables included age, histopathological subtype, FIGO stage, lymph node status, pre-treatment serum SCCA, platelet-to-lymphocyte ratio [PLR], neutrophil-to-lymphocyte ratio [NLR], albumin-to-fibrinogen ratio [AFR], and PIV (calculated as neutrophil × platelet × monocyte counts/lymphocyte count). Short-term efficacy was assessed by the complete response rate (CRR) at 6 months post-treatment. Long-term survival was assessed by overall survival (OS) and progression-free survival (PFS).
Results
Multivariate logistic regression identified tumor size ≥ 4 cm, NLR ≥ 3.32, and PIV ≥ 350.15 as independent risk factors for poor short-term response. Multivariate Cox analysis revealed that tumor size ≥ 4 cm, FIGO stage IVA, SCCA ≥ 1.84 ng/mL, and PIV ≥ 350.15 were independent adverse prognostic factors for OS. For PFS, independent predictors included moderate/poor differentiation, FIGO stage IVA, SCCA ≥ 1.84 ng/mL, and PIV ≥ 350.15. Adding PIV to a clinical model (FIGO stage + SCCA) improved the prediction of OS.
Conclusions
PIV provides independent prognostic information and may serve as a practical tool for risk stratification and personalized treatment in LACC.
Förderung
- National Natural Science Foundation of China
- Wuxi Municipal Health Commission
- Wuxi Bureau of Science and Technology
Zitieren
APA
Gu, L., Chen, H., Feng, Y., Huang, W., & Cao, J. (2026). Prognostic Utility of the Pan-Immune-Inflammation Value (PIV) in Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy. Cancers, 18(22), 3605. https://doi.org/10.3390/cancers18223605
Vancouver
Gu L, Chen H, Feng Y, Huang W, Cao J. Prognostic Utility of the Pan-Immune-Inflammation Value (PIV) in Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy. Cancers. 2026;18(22):3605. doi:10.3390/cancers18223605
BibTeX
@article{Gu2026,
author = {Gu, Liming and Chen, Hui and Feng, Yang and Huang, Wenzhi and Cao, Jinming},
title = {Prognostic Utility of the Pan-Immune-Inflammation Value (PIV) in Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy},
journal = {Cancers},
year = {2026},
volume = {18},
number = {22},
pages = {3605},
doi = {10.3390/cancers18223605}
}
EUVIMED